Dl-3-n-butylphthalide is effective for demyelination: a case-combined study

Clin Neurol Neurosurg. 2015 Oct:137:83-8. doi: 10.1016/j.clineuro.2015.06.024. Epub 2015 Jul 2.

Abstract

Demyelinating diseases is common in neurology department, but its treatment is still not clear. A 40-year-old male who was addicted in heroin was hospitalized and presented worsening altered mental status in hospital. Brain magnetic resonance imaging (MRI) revealed a symmetrical diffuse long T1 and long T2 time abnormalities in the white matter of cerebral hemispheres which indicated demyelination. High-dose intravenous methylprednisolone was not effective as expected. However, after treatment with intravenous Dl-3-n-butylphthalide for 7 days, the patient's symptoms and features of electroencephalogram (EEG) and MRI improved. Hence, ethidium bromide was used in a rat model to evaluate the positive effects of Dl-3-n-butylphthalide in demyelinating diseases. The results indicated that Dl-3-n-butylphthalide prevented white matter from demyelinating by regulating apoptosis through multiple approaches.

Keywords: Apoptosis; Demyelination; Dl-3-n-butylphthalide; Heroin; Mitochondria.

MeSH terms

  • Adult
  • Animals
  • Benzofurans / administration & dosage
  • Benzofurans / therapeutic use*
  • Brain / diagnostic imaging*
  • Demyelinating Diseases / drug therapy*
  • Demyelinating Diseases / pathology
  • Disease Models, Animal
  • Electroencephalography / methods
  • Humans
  • Magnetic Resonance Imaging / methods
  • Male
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use*
  • Radiography
  • Rats, Sprague-Dawley
  • Treatment Outcome

Substances

  • Benzofurans
  • 3-n-butylphthalide
  • Methylprednisolone